Staph Aureus Vaccines & Therapeutics R&D Pipelines Discussed by La Merie in New Report Available at MarketPublishers.com
31 Oct 2013 • by Natalie Aster
LONDON – Presently, Staphylococcus aureus is considered to be a major cause of surgical site infections (SSI) as well as infections that occur in hospital intensive care units (ICUs). In spite of a clear and increasing medical need for vaccines and effective therapeutics to combat Staphylococcus aureus, the number of new antibiotics approved is decreasing, whilst bacteria are becoming more resistant to the currently available drugs. Recently, the development of specific therapies and vaccines for staphylococcal diseases has caused a huge wave of attention, as highly virulent Staphylococcus aureus strains have emerged outside healthcare establishments.
Still, new approaches based on the combination of regularly selected antigens have shown rather promising results. Another important way to approach the treatment of staphylococcal infections is passive immunotherapy with monoclonal therapeutic antibodies against staphylococcus aureus. At present, more improved and targeted antibiotics for the prevention and treatment of staphylococcus aureus disease are in development.
New research report “Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives)” prepared by La Merie Publishing provides a competitor evaluation in the field of the development of new molecules for the prevention and treatment of staphylococcus aureus infections.
The research study is an essential source of accurate data on the currently active projects in R&D of proteins, antibodies, vaccines, peptides and small molecules for the prevention as well as treatment of staphylococcus aureus infections. Furthermore, the research provides a listing of corporate R&D pipelines of staphylococcus aureus vaccines and therapeutics. Competitor projects disclose information on: drug codes; target/mechanism of action; company; class of compound; indication; product category; and R&D stage.
Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives)
Published: October, 2013
Price: US$ 662.00
Other Competitor Analysis Reports by La Merie Publishing Include:
- Competitor Analysis: PTH Receptor Agonists, Teriparatide Biosimilars and Biosuperiors
- Competitor Analysis: Pim Kinase Inhibitors
- Competitor Analysis: Wnt Pathway Inhibitors
- Competitor Analysis: Bruton’s Tyrosine Kinase (BTK) Inhibitors
- Competitor Analysis: Focal Adhesion Kinase (FAK) Inhibitors
More new research reports by the publisher can be found at La Merie Publishing page.